Protocol Ledger

NCT03938545 · Phase II · TERMINATED

ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )

Interventional Phase II clinical trial protocol NCT03938545 sponsored by Immunovant Sciences in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-07-23 Enrollment: 65 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03938545
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)65 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03938545
Protocol FieldVerified Registry Value
NCT IdentifierNCT03938545
Consolidated Lead SponsorImmunovant Sciences
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment65 participants (ACTUAL)
Registered Start Date2019-07-23
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI